Navigation Links
Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Date:11/21/2011

$60 Billion by 2015.[3]

References:

  1. Report by the Institute of Medicine, Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, June 2011
  2. Report by the Institute of Medicine, Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, June 2011
  3. Global Industry Analysts Inc. 2010, Pain Management: A Global Strategic Business Report.

http://www.strategyr.com/Pain_Management_Market_Report.asp

About Convergence Pharmaceuticals

Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company, led by CEO Clive Dix, was formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline ("GSK").

Convergence Pharmaceuticals has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signalling through modulation of specific ion-channels. There are two molecules in its development portfolio for the treatment of chronic pain, CNV1014802 which is in Phase II development for the treatment of lumbosacral radiculopathy (LSR) and CNV2197944 which is in Phase I development. Clinical Development activities for CNV2197944 are being conducted by Convergence Pharmaceuticals Ltd on behalf of Calchan Ltd.

Convergence Pharmaceuticals is well funded and raised $35.4 million in Series A financing from a syndicate of leading European and US financial institutions. For more information please go to the Company's website at http://www.convergencepharma.com

For more information about Convergence Pharmaceu
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
2. Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
5. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
6. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
9. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results and Recent Operational Highlights
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Biovista Inc. freut ... von 2015 bekanntgeben zu können. Hierbei handelt es ... Biovista unterstützt mit seiner Möglichkeit der ... anderer Krankheiten als denen, für die ein Medikament ... sein Team bei der Wylder Nation Foundation bei ...
(Date:9/2/2015)... ... 2015 , ... Genedata, a leading provider of advanced software ... ® version 13.0 at ELRIG Drug Discovery 2015. This latest version of the ... new capabilities. Screener now supports High Throughput Flow Cytometry (HT-Flow) and Drug Metabolism ...
(Date:9/1/2015)... Sept. 1, 2015 Prostate cancer ... in American men. One in seven men will ... new cases are diagnosed annually. That said, not ... a powerful new technique, MRI Fusion Biopsy, to ... cancer lesions, treating only the affected areas and ...
(Date:9/1/2015)... , Sept. 1, 2015 The ... Eric Floyd , Ph.D., MBA as Chief Science ... In this newly created role, Dr. Floyd will ... as a portfolio of pre-commercial and post approval ... affairs and medical communications.  Dr. Floyd brings decades ...
Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3
... GenVault Corporation, the,leader in room temperature biosample ... that David Wellis, Ph.D.,GenVault,s President and CEO will ... from October 26-28 in La Jolla, CA. During ... the company including,recent customer, technical and strategic developments., ...
... Genomics, Proprietary microRNA Technologies and Strong IP Position to Develop a Wide ... Plant-Based Applications, The Company has Recently Secured Up to $1.5M From Private Investors, Which, ... ... microRNAs Correlated With Algal Oil Content ...
... GeneThera, Inc.,(Pink Sheets: GTHR), announced today that it ... of the University of New Mexico,(UNM), giving GeneThera an ... to a vaccine developed at UNM,s Health Sciences Center,that ... of the,E. coli bacteria in cattle., The technology ...
Cached Biology Technology:Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 2Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 3Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 4STC.UNM Signs License Option Agreement With GeneThera for E. coli O157:H7 Vaccine 2STC.UNM Signs License Option Agreement With GeneThera for E. coli O157:H7 Vaccine 3STC.UNM Signs License Option Agreement With GeneThera for E. coli O157:H7 Vaccine 4
(Date:8/18/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ) has ... Authentication & Identification Market: Focus On Modality, Motility ... report to their offering. The ... expected to grow at an estimated CAGR of ... $25 billion (approximately) by 2020 as per the ...
(Date:8/12/2015)...  New research unveiled at Black Hat 2015 ... steal users, fingerprints. Information released today by HYPR ... on mobile devices, making the security of this ... mobile devices, HYPR Corp. recently released a biometric ... with strong cryptographic security. More information on this ...
(Date:8/10/2015)... The latest 364 page report from business intelligence ... border security market . Visiongain assesses that ... Now: Border security is hard to achieve and harder ... issue you need to know about - and more importantly, ... how this will impact your company and the border security ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... Rochelle, NY, April 29, 2011Videoscopy, a groundbreaking ... publication, Journal of Laparoendoscopic & Advanced ... Mary Ann Liebert, Inc., publishers ( http://www.liebertpub.com ... peer-reviewed surgical and microinvasive demonstrations of the ...
... Academy of Sciences will launch the most comprehensive scientific ... terrestrial and marine life forms from the tops of ... They will be joined by colleagues from the University ... National Museum and the Philippines Bureau of Fisheries and ...
... eavesdropping on complex signals from a remote Wisconsin lake ... death knell--of the impending collapse of the lake,s aquatic ... Science by a team of researchers led by Stephen ... is the first experimental evidence that radical change in ...
Cached Biology News:Groundbreaking minimally invasive surgical videojournal launched by Mary Ann Liebert Inc. 2California Academy of Sciences launches scientific expedition to the Philippines 2California Academy of Sciences launches scientific expedition to the Philippines 3California Academy of Sciences launches scientific expedition to the Philippines 4California Academy of Sciences launches scientific expedition to the Philippines 5A tale of 2 lakes: One gives early warning signal for ecosystem collapse 2A tale of 2 lakes: One gives early warning signal for ecosystem collapse 3A tale of 2 lakes: One gives early warning signal for ecosystem collapse 4
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Rac1/2/3 (L129) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
In plasmid or lambda vector. Please inquire for more details!...
ANTI-RAT ADHESION MARKERS, CDs, CYTOKINES, ETC Rat ICAM PE - Mouse IgG1...
Biology Products: